Biologics Safety Testing Market worth $ 4.90 Billion by 2022 – Exclusive Report by MarketsandMarkets™

Biologics Safety Testing Market

Pune, India, 2020-Jun-12 — /EPR Network/ —

Biologics are pharmaceutical products that are extracted from biological sources. Biologics safety testing is carried out by manufacturers to detect contaminants like bacterial toxins, mycoplasma, and viruses. It is a mandatory process in these companies for the quality control of raw materials as well as for process control and validation of end products.

What the Biologics Safety Testing Market Looks Like?

The global biologics safety testing market is expected to reach USD 4.90 Billion by 2022 from USD 2.75 Billion in 2017, at a CAGR of 12.2% during forecast period. North America to account for the largest market size during the forecast period.

The major factors driving the growth of this market are the growth in pharmaceutical & biotechnology industry driven by government support, the positive trend of R&D investment in the life science sector, increasing number of drug launches, and high incidence & large economic burden of chronic diseases. In the coming years, emerging markets and increasing pharmaceutical outsourcing are expected to offer growth opportunities for players in the biologics safety testing market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144

What Drives the Biologics Safety Testing Market?

The growth of the global market for Ambulatory Surgical Centers Market is primarily influenced by the following factors:

  • Growth in Pharmaceutical and Biotechnology Industries Driven By Government Support
  • Positive Trend of R&D Investments in Life Science
  • Increase in Number of Drug Launches
  • High Incidence and Large Economic Burden of Chronic Diseases

By application, Vaccine and Therapeutics Development segment to record the highest CAGR during the forecast period

Vaccine and Therapeutics Development segment is projected to register a higher CAGR during the forecast period. Factors such as the rising prevalence of diseases, increasing initiatives for immunization, and increasing company investments in vaccine development are expected to drive the growth of this market segment.

By test type, endotoxin test segment to record the highest CAGR during the forecast period

Endotoxin test segment is projected to register a higher CAGR during the forecast period. The market is mainly driven by the increase in disease prevalence and growth in the number of drug launches. Moreover, Endotoxin testing is used in cell therapy, monoclonal antibody testing, vaccine testing, gene therapy, and drug development.

The geographical regions mapped in the report are:

  • North America
  •  Europe
  •  Asia-Pacific
  • Middle East & Africa

Geographical growth scenario of Biologics Safety Testing Market:

North America is expected to account for the largest share of this market. The strong R&D trend in life sciences and growth in pharmaceutical industries will drive the biologics safety testing market in the North American region.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=34624144

Leading market players and strategies adopted

The prominent players operating in the Biologics Safety Testing Market include Lonza Group LTD, Charles River Laboratories, Merck KGaA, SGS SA, WuXi Apptec, Thermo Fisher Scientific Inc, Sartorius AG, Cytovance Biologics, Inc, Pace Analytical Services Inc, and Toxikon Corporation.

Matched content

Editor’s pick

Express Press Release Distribution